MARKET

NBIX

NBIX

Neurocrine
NASDAQ

Real-time Quotes | Nasdaq Last Sale

103.54
+1.95
+1.92%
Opening 14:19 01/29 EST
OPEN
101.31
PREV CLOSE
101.59
HIGH
103.81
LOW
101.31
VOLUME
320.37K
TURNOVER
--
52 WEEK HIGH
119.65
52 WEEK LOW
71.85
MARKET CAP
9.54B
P/E (TTM)
613.03
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of NBIX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 19 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

NBIX News

  • Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
  • Zacks.1d ago
  • Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2019 Financial Results
  • PR Newswire.01/20 21:30
  • Zacks.com featured highlights include: Zumiez, Neurocrine Biosciences and Covanta
  • Zacks.01/20 15:02
  • Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $121
  • Benzinga.01/17 13:28

More

Industry

Biotechnology & Medical Research
-0.03%
Pharmaceuticals & Medical Research
+0.42%

Hot Stocks

Name
Price
%Change

About NBIX

Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson's disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.
More

Webull offers Neurocrine Biosciences, Inc. (NBIX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.